Relugolix: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), HAS (France) and NICE (England), among others, recommended or restricted relugolix, while AOTMIT (Poland) did not recommend it.
The record spans 3.8 years, opening at CIPM (Spain) on 2 Jun 2022 and running to 1 Apr 2026.
CIPM (Spain) changed its position: not recommended on 2 Jun 2022, recommended by 17 Jul 2024, after a resubmission.
No assessment is on file from PBAC (Australia) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
The file is active: 13 of 17 records date from 2023 or later.
3 distinct indication wordings are recorded for relugolix by the agencies that label one in English (AWMSG, NICE and SMC).
CIPM (Spain) was first to assess relugolix, on 2 Jun 2022; SMC (Scotland) did not open a file until 7 Oct 2024 — a moderate spread of 2.3 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 5 years in total.
3 of the 10 agencies here assessed relugolix more than once, ZIN (Netherlands) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for relugolix.
The full ledger for relugolix reads 12 recommended, 2 not recommended, 1 advice and 1 deferred to NICE, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| ZIN (Netherlands) | 30 Sep 2025 | Advies - laten vervallen vergoedingsvoorwaarden relugolix in combinatie met estradiol en norethisteronacetaat (Ryeqo®) | advice published | source |
| SMC (Scotland) | 7 Oct 2024 | - For the treatment of adult patients with advanced hormone-sensitive prostate cancer. - For the treatment of high-risk localised and locally advanced hormone dependent p… | accepted | source |
| NICE (England) | 14 Aug 2024 | NICE TA995 | recommended | source |
| AWMSG (Wales) | 1 Jul 2024 | For the treatment of adult patients with advanced hormone-sensitive prostate cancer | excluded, NICE appraised | source |
| CIPM (Spain) | 2 Jun 2022 | Indicaciones terapéuticas autorizadas: Tratamiento de los síntomas moderados a graves de los miomas uterinos en mujeres … | not financed by the SNS (financed 2022-09) | source |
12 further decisions for relugolix, across 7 agencies, are not shown here. They include the most recent record on file, 1 Apr 2026 from HAS (France); its outcome is in the subscriber dataset. They link to 11 further source documents.
Related molecules
- enzalutamide — same ATC class L02B — Endocrine therapy
- darolutamide — same ATC class L02B — Endocrine therapy
- apalutamide — same ATC class L02B — Endocrine therapy
- abiraterone — same ATC class L02B — Endocrine therapy
- fulvestrant — same ATC class L02B — Endocrine therapy
- elacestrant — same ATC class L02B — Endocrine therapy
Coverage: 17 decisions for relugolix from 10 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class L02B — Endocrine therapy. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.